Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 5/20 | 0.79 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15569844 | 1.00 | STAT3 (0.79) | STAT3ADRB2HTR1AATMKDM4E | |
| SCHEMBL3578334 | 0.91 | STAT3 (0.87) | STAT3ADRB2HTR1AATMKDM4E | |
| SCHEMBL10772217 | 0.90 | STAT3 (0.65) | STAT3HTR1AATMKDM4ECA2 | |
| SCHEMBL10772214 | 0.89 | STAT3 (0.77) | STAT3ADRB2HTR1AATMKDM4E | |
| SCHEMBL12969998 | 0.87 | ADRB2 (0.74) | STAT3ADRB2HTR1AATMPOLB | |
| SCHEMBL10027126 | 0.87 | STAT3 (0.79) | STAT3ADRB2HTR1AATMKDM4E | |
| SCHEMBL6049246 | 0.84 | STAT3 (0.57) | STAT3ADRB2HTR1AATMKDM4E | |
| SCHEMBL19354485 | 0.83 | LDHA (0.60) | STAT3ATMKDM4ECA2POLB | |
| SCHEMBL15236787 | 0.83 | STAT3 (0.73) | STAT3ATMKDM4ECA2POLB | |
| SCHEMBL15570024 | 0.83 | LDHA (0.60) | STAT3ATMKDM4ECA2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041019-A1 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20120022040-A1 | ANTIMICROBIALS | AMPLYX PHARMACEUTICALS, INC. | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022040-A1 | ANTIMICROBIALS | PAM, MPO, OXA1L | STAT3 4312/4885ADRB2 2837/4885HTR1A 3504/4885 |
| US-20120041019-A1 | PROTEASE INHIBITORS | SERPINB1, PREP, DNPEP | STAT3 3020/4885ADRB2 4834/4885HTR1A 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.